Standard BioTools
LAB
80 hedge funds and large institutions have $182M invested in Standard BioTools in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 6 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 19
72% more capital invested
Capital invested by funds: $106M → $182M (+$76.2M)
33.36% more ownership
Funds ownership: 89.74% → 123.1% (+33%)
17% more call options, than puts
Call options by funds: $655K | Put options by funds: $558K
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0% more funds holding
Funds holding: 80 → 80 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Neuberger Berman Group
New York
|
+$14.1M |
| 2 |
LCS
Levin Capital Strategies
New York
|
+$12.4M |
| 3 |
Primecap Management
Pasadena,
California
|
+$6.27M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
+$4.62M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$483K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$397K |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$274K |
| 4 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$164K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$123K |
LAB Hedge Fund Activity: Q3 2017 in Review
80 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2017, worth a combined $182M — up 72% from $106M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LAB positions and 6 closed out — a net gain of 1 holder — while 35 added to existing stakes and 19 trimmed.
The largest buyer was Neuberger Berman Group, adding an estimated $14.1M. The largest seller was Adage Capital Partners, cutting an estimated $483K.
- 80 institutional investors held Standard BioTools (LAB) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $182M of Standard BioTools stock for Q3 2017, up 72% quarter-over-quarter.
- 7 funds opened new Standard BioTools positions in Q3 2017 and 6 closed out, a net change of +1 holder.
- The largest Standard BioTools buyer in Q3 2017 was Neuberger Berman Group, an estimated $14.1M added.
- The largest Standard BioTools seller in Q3 2017 was Adage Capital Partners, an estimated $483K sold.
Based on aggregated 13F filings for Q3 2017.